SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Metabolic / IncretinResearch peptide

Survodutide

aka BI 456906

Dual GLP-1 / glucagon receptor agonist studied for obesity and MASH.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Survodutide is a once-weekly dual agonist of GLP-1 and glucagon receptors developed for obesity and metabolic-dysfunction-associated steatohepatitis (MASH).

Source
  • Investigational pharmaceutical
Forms
  • Subcutaneous injection

Mechanism of action

Combines GLP-1-mediated appetite and glycemic control with glucagon-mediated energy expenditure and hepatic fat mobilization.

Pathways
  • · GLP-1 receptor
  • · Glucagon receptor
  • · Hepatic lipid oxidation
Hormones
  • · GLP-1
  • · Glucagon

How it acts on the body

Glucagon at the right dose increases energy expenditure and hepatic fat oxidation, but used alone it raises blood glucose. Combining it with GLP-1 signaling cancels the glycemic downside while keeping the metabolic upside.

In phase 2 obesity trials, survodutide produced double-digit percent weight loss with notable reductions in liver fat, supporting parallel development in MASH where hepatic fat resolution is the primary endpoint.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

GLP-1 signalingIncreases
Sustained receptor activation.
Glucagon signalingIncreases
Energy expenditure and hepatic lipid oxidation.
Hepatic triglyceride contentDecreases
Direct hepatic effect in MASH.

Effects on the body

Decreases
Body weight
Decreases
Hepatic steatosis in MASH

Organ system effects

Liver

Direct lipid mobilization.

Endocrine

Dual incretin and glucagon-axis stimulation.

Digestive / Gut

Delayed gastric emptying.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Targets both weight and liver fat
  • Dual mechanism

Potential side effects

Common
  • · Nausea
  • · Vomiting
  • · Diarrhea
Rare
  • · Injection-site reactions
Serious
  • · Pancreatitis and gallbladder events under monitoring

Drug interactions

Insulin or sulfonylureas
Hypoglycemia risk requires dose adjustment.
moderate

Pairing context

Often combined with
  • Structured lifestyle intervention
    Maximizes durable weight and metabolic response.
Avoid combining with
  • MEN-2 syndrome
    Class-level caution with incretin therapies.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.